Biotech Stocks Dominate Monday’s Top 10 Gainers

7. ImmunityBio Inc. (NASDAQ:IBRX)

ImmunityBio grew for a second day on Monday as investor funds started flocking to stocks with lesser risks from the ongoing trade tensions globally while repositioning portfolios ahead of its Investor Day tomorrow, April 15.

According to the company, it plans to announce in-depth updates about its business operations, key timelines, ongoing clinical trials, and recent research and development advancements.

IBRX is a clinical-stage biotech company developing immune-enhancing therapies for cancer and infectious diseases. It is underway with its global expansion for its novel immunotherapy ANKTIVA, which aims to treat unresponsive non-muscle invasive bladder cancer carcinoma in situ (CIS).

Just recently, IBRX submitted a marketing authorization request from the European Medicines Agency for the review and assessment of ANKTIVA. If approved by the EMA, IBRX would be able to sell ANKTIVA in 27 countries in Europe, including Norway, Iceland, and Liechtenstein.